Last updated: February 27, 2026
What is NDC 61314-0019?
NDC 61314-0019 corresponds to Viltolactus," a targeted therapy drug approved in recent years. The drug is used primarily for specific indications, with its market footprint established in oncology treatment areas.
Market Size and Demand Drivers
Therapeutic Area and Indications
Viltolactus is approved for use in oncology, specifically for adult and pediatric patients with certain cancer types. Its adoption hinges upon:
- Expansion of approved indications
- Clinical efficacy compared to existing therapies
- Adoption rates by oncologists and hospitals
Market Size Estimates
Analysts estimate the global oncology drug market was valued at approximately $150 billion in 2022, with targeted therapies accounting for about 45% of this value.
- Viltolactus's immediate market niche relates to a subset of solid tumors, which represent roughly 10-15% of the total targeted therapy segment.
Competitive Landscape
Key competitors include drugs like osimertinib (Tagrisso), alectinib (Alecensa), and emerging biosimilars.
| Competitor |
Market Cap ($B) |
Approximate Market Share (%) |
Years on Market |
Approval Status |
| Osimertinib (Tagrisso) |
25 |
20 |
2015 |
Approved for NSCLC |
| Alectinib (Alecensa) |
15 |
10 |
2017 |
Approved for ALK+ NSCLC |
| Other targeted therapies |
Varies |
15-20 |
2010–present |
Multiple indications |
Note: NDC 61314-0019 is newer, with initial market entry in 2021.
Price Projections
Current Pricing
- Average wholesale price (AWP): Approximately $10,000–$15,000 per treatment course
- Patient out-of-pocket costs: Ranges significantly based on insurance coverage but generally $2,000–$5,000 per course for insured patients.
Factors Influencing Future Pricing
- Market penetration: Early adoption has been steady with a growing number of approved indications.
- Competitive discounts: Payers negotiate rebates that reduce net prices.
- Regulatory shifts: New approvals can impact pricing strategies.
Price Trajectory Projections (Next 5 Years)
| Year |
Projected Price Range per Course |
Assumptions |
| 2023 |
$10,000 – $12,000 |
Initial stabilization, competitive pressures begin to influence prices |
| 2024 |
$9,500 – $11,500 |
Rebate utilization increases, some price erosion |
| 2025 |
$9,000 – $11,000 |
Market maturity, new entrants influence pricing |
| 2026 |
$8,500 – $10,500 |
Heightened competition and generic biosimilars entering market |
| 2027 |
$8,000 – $10,000 |
Cost containment policies impact prices |
Revenue Estimates
By 2027, adopting approximately 10,000 treatment courses annually–expected in top markets (U.S., EU, emerging economies):
| Financial Metric |
Projected Revenue (2027) |
| At $8,000 per course |
$80 million |
| At $10,000 per course |
$100 million |
Regulatory and Policy Impact
- Reimbursement landscape: Payers prefer lower-cost alternatives, pressuring manufacturers to justify premium pricing based on clinical benefits.
- Patent protectiveness: Patent exclusivity extends into 2030, supporting higher price points initially.
- Potential biosimilars: Entry of biosimilars after patent expiry could lower prices substantially.
Key Takeaways
- NDC 61314-0019 targets niche oncology indications with a rapidly expanding market.
- Its current price of $10,000–$15,000 per course is justified by clinical benefits but faces downward pressure from competitive dynamics.
- Market penetration is expected to grow, with prices declining gradually over five years.
- Revenue potential hinges on indication expansion, payer negotiations, and competitive responses.
FAQs
1. How does the pricing of NDC 61314-0019 compare to similar targeted therapies?
It is roughly in line with drugs like osimertinib, though slightly lower, reflecting initial market exclusivity and size of indications.
2. Could biosimilars impact the price of NDC 61314-0019?
Yes. Biosimilars entering the market post-patent expiry could reduce prices by 30-50%.
3. What factors most influence future demand for this drug?
Indication expansion, clinician adoption, and reimbursement policies are chief factors.
4. What markets contribute most to revenue growth?
The U.S. remains the largest, followed by Europe and select Asian countries with emerging healthcare infrastructure.
5. What regulatory changes could alter price trajectory?
Expanded approvals, added indications, or changes in reimbursement policies could either increase or decrease prices.
References
- IQVIA. (2022). Global Oncology Market Report.
- FDA. (2021). Approval summaries for targeted oncology therapies.
- Evaluate Pharma. (2022). Oncology drug pricing and market projections.
- Health Economics. (2022). Impact of biosimilars on oncology drug pricing.
- U.S. Centers for Medicare & Medicaid Services. (2022). Reimbursement policies and drug pricing.
[1] IQVIA. (2022). Global Oncology Market Report.
